Key Points:
- UK based Codagenix Inc. stated that Serum Institute has begun potential vaccine making for them.
- The human trials will begin by the end of the year.
- The vaccine will be given intranasally and not through an injection.
- More vaccines are being developed to curb the virus that has led to a pandemic.
On Tuesday, Codagenix Inc said that the Serum Institute of India has started manufacturing the potential Covid-19 vaccine. The early stage of human trials is expected to begin by the end of 2020 in the United Kingdom.
Update https://t.co/xuA2GF1wCI
— SerumInstituteIndia (@SerumInstIndia) September 16, 2020
Codagenix is a clinical stage synthetic biology company that uses software to recode the genetic data of viruses, viruses to put off viral infections or treat solid tumors. Codagenix’s CDX-005 vaccine that will be intranasally given instead of an injection, will be developed by The Serum Institute, the world’s largest vaccine maker by number of doses produced.
While developing its own vaccine, Serum Institute is working on quite a few vaccine candidates for the novel coronavirus. The list includes mass-producing the one from AstraZeneca-Oxford University that has attracted global headlines. More than 150 potential vaccines are being developed and tested globally, with 38 in human trials, and candidates from Moderna Inc, Pfizer Inc and AstraZeneca Plc are already in late-stage trials.
Indian Serum Institute received required regulatory authorization from the Review Committee on Genetic Manipulation (RCGM) of India’s Department of Biotechnology (DBT) for manufacturing Codagenix’s COVID-19 vaccine. Serum Institute will begin manufacturing for large-scale safety and effectiveness studies plus equipping to meet global vaccine supply requirements, said Codagenix.
